Neurolief has obtained the CE mark for adaptive digital treatment of its Relivion non-invasive. Neurolief is a known developer of digital therapeutics brain neuromodulation technology.
On basis of the announcement of the new CE mark, the new development will allow Neurolief to sell, distribute and market the Relivion device as an over-the counter therapy within the scope of countries that participate with the Agreements on Mutual Recognition of Conformity Assessment and of the European Union.
“This CE mark for the Relivion system marks a vital step in providing patients with alternative, non-drug technology-driven treatments,” commented Shmuel Shany, co-founder and CEO, Neurolief.
According to reports, the Relivion is the first of its kind, a non-invasive, adaptive multi-channel technology of brain neuromodulation. Furthermore, it also an effective therapy, involved without the costs and risks, associated with the invasive procedures and without the knowledge of side effects based on medications. Previously this kind of therapy was possible only through implanted devices. The Relivion system on the other hand is safe and simple for patients. They can self-administer the system from home.
The Neurolief’s Relivion consists of an adjustable headset which ultimately provides precise and mosulated pulses at a time to six branches of trigeminal and occipital nerves. This is made possible through several adaptive output channels placed around the patient’s head. Moreover, the advanced cloud-enabled device also helps to connect with a proprietary mobile app, which enables the knowledge of personalized treatment for every patient.
“We designed the Relivion to be a self-administered, safe and attainable alternative to high-cost and high-risk surgical implants, accelerating migraine relief for migraine sufferers in a non-invasive manner. We believe the Relivion will be instrumental in giving patients more rapid relief, increased productivity, and the ability to get back to their lives,” said Shany.